Structural factors and their influence on the use of novel antidiabetic agents: Making the case for increased awareness and access to clinical pharmacy services

Type 2 diabetes (T2D) affects over 38 million Americans, leading to significant health complications and substantial healthcare costs. Novel antidiabetic medications, such as SGLT2 inhibitors and GLP‐1 receptor agonists, have shown promise in improving glycemic control and reducing cardiovascular risks. However, their underuse, particularly among minority populations, remains a concern. This review examines the impact of structural factors, including socioeconomic determinants and historical practices like redlining, on the utilization of new antidiabetic agents. Disparities in T2D outcomes are driven by inadequate access to care and neighborhood characteristics. Addressing these issues requires comprehensive strategies, including the integration of pharmacist support to enhance medication adherence and overall T2D management. Understanding the influence of structural racism on healthcare disparities is crucial for improving access and outcomes for all patients.